Fayez Sarofim & CO Gilead Sciences, Inc. Transaction History

Fayez Sarofim & CO

$38.7 Billion
Q3 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $443,628 - $511,981	-7,025 Reduced 59.86%	4,710 $323,000
Q4 2023 Feb 14, 2024	SELL	$73.27 - $83.09 $283,042 - $320,976	-3,863 Reduced 24.77%	11,735 $950,000
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $429,813 - $468,934	5,813 Added 59.41%	15,598 $1.17 Million
Q2 2023 Aug 14, 2023	SELL	$76.01 - $86.7 $2.66 Million - $3.04 Million	-35,009 Reduced 78.16%	9,785 $754,000
Q1 2023 May 11, 2023	BUY	$77.31 - $88.08 $695 - $792	9 Added 0.02%	44,794 $3.72 Million
Q4 2022 Feb 13, 2023	SELL	$62.32 - $89.47 $12,464 - $17,894	-200 Reduced 0.44%	44,785 $3.84 Million
Q3 2022 Nov 14, 2022	SELL	$59.54 - $68.01 $57,813 - $66,037	-971 Reduced 2.11%	44,985 $2.78 Million
Q2 2022 Aug 12, 2022	SELL	$57.72 - $65.01 $688,657 - $775,634	-11,931 Reduced 20.61%	45,956 $2.84 Million
Q1 2022 May 16, 2022	SELL	$57.92 - $72.58 $3.97 Million - $4.97 Million	-68,544 Reduced 54.21%	57,887 $3.44 Million
Q4 2021 Feb 11, 2022	BUY	$64.88 - $73.64 $1.18 Million - $1.34 Million	18,211 Added 16.83%	126,431 $9.18 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $526,357 - $567,881	-7,776 Reduced 6.7%	108,220 $7.56 Million
Q2 2021 Aug 13, 2021	BUY	$63.47 - $69.35 $1.64 Million - $1.79 Million	25,866 Added 28.7%	115,996 $7.99 Million
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $119,400 - $136,235	-1,990 Reduced 2.16%	90,130 $5.83 Million
Q4 2020 Feb 11, 2021	SELL	$56.65 - $64.55 $242,858 - $276,725	-4,287 Reduced 4.45%	92,120 $5.37 Million
Q3 2020 Nov 13, 2020	SELL	$62.1 - $78.08 $176,364 - $221,747	-2,840 Reduced 2.86%	96,407 $6.09 Million
Q2 2020 Aug 11, 2020	BUY	$72.34 - $84.0 $1,446 - $1,680	20 Added 0.02%	99,247 $7.64 Million
Q4 2019 Feb 14, 2020	SELL	$61.62 - $67.78 $295,776 - $325,344	-4,800 Reduced 4.61%	99,227 $6.45 Million
Q3 2019 Nov 13, 2019	SELL	$62.51 - $69.0 $422,880 - $466,785	-6,765 Reduced 6.11%	104,027 $6.59 Million
Q2 2019 Aug 09, 2019	SELL	$61.87 - $69.38 $508,571 - $570,303	-8,220 Reduced 6.91%	110,792 $7.49 Million
Q1 2019 May 14, 2019	SELL	$62.53 - $70.05 $372,678 - $417,498	-5,960 Reduced 4.77%	119,012 $7.74 Million
Q4 2018 Feb 13, 2019	SELL	$60.54 - $79.0 $38,745 - $50,560	-640 Reduced 0.51%	124,972 $7.82 Million
Q3 2018 Nov 14, 2018	SELL	$71.28 - $78.92 $1.5 Million - $1.66 Million	-21,020 Reduced 14.34%	125,612 $9.7 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $1.55 Million - $1.8 Million	-23,820 Reduced 13.97%	146,632 $10.4 Million
Q1 2018 May 10, 2018	SELL	$72.84 - $88.8 $3.72 Million - $4.54 Million	-51,072 Reduced 23.05%	170,452 $12.9 Million
Q4 2017 Feb 13, 2018	SELL	$71.15 - $83.52 $2.05 Million - $2.4 Million	-28,747 Reduced 11.49%	221,524 $15.9 Million
Q3 2017 Nov 08, 2017	BUY	$72.11 - $85.47 $18 Million - $21.4 Million	250,271	250,271 $20.3 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

Black Rock Inc. New York, NY

121M
Shares

$11.2 Billion
0.19% of portfolio
Vanguard Group Inc Valley Forge, PA

115M
Shares

$10.7 Billion
0.18% of portfolio
Capital World Investors Los Angeles, CA

76.5M
Shares

$7.09 Billion
1.03% of portfolio
Capital Research Global Investors Los Angeles, CA

61.8M
Shares

$5.72 Billion
1.12% of portfolio
State Street Corp Boston, MA

60.2M
Shares

$5.57 Billion
0.21% of portfolio

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fayez Sarofim & CO, based on Form 13F filings with the SEC.

News

Stay updated on Fayez Sarofim & CO with notifications on news.

Account